Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/24/2019 |
| Start Date: | February 1, 2018 |
| End Date: | March 2020 |
| Contact: | Krystal Dawkins |
| Email: | Krystal.Dawkins@nyumc.org |
| Phone: | 212-263-7300 |
This is a prospective, randomized, single blinded trial involving human subjects. The goal of
this study is to determine an optimal location (proximal or distal) for the nerve block and
whether it will make a difference in how much opioid the patient will receive during and
after surgery. Ultrasound will identify the adductor canal and the proximal end of the
adductor canal/apex of the femoral triangle to determine the location of the blocks.
Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB
proximal to true AC with bupivacaine 0.5% 20cc
this study is to determine an optimal location (proximal or distal) for the nerve block and
whether it will make a difference in how much opioid the patient will receive during and
after surgery. Ultrasound will identify the adductor canal and the proximal end of the
adductor canal/apex of the femoral triangle to determine the location of the blocks.
Their will be two randomized groups: 1. ACB within true AC with bupivacaine 0.5% 20cc2. ACB
proximal to true AC with bupivacaine 0.5% 20cc
Inclusion Criteria:
- Patients undergoing unilateral, ACL surgery with allograft.
- Patients who consent to be randomized.
- Patients must be English proficient.
Exclusion Criteria:
- Patients younger than 18 or older than 75 years of age;
- Patients with a history of chronic pain or who are taking medications intended to
treat chronic pain such as strong opioids;
- Patients with history of neurologic disorder that can interfere with pain sensation;
- Patients with a history of drug or alcohol abuse;
- Patients who are unable to understand or follow instructions;
- Patients with an allergy or a contraindication to any of the medications used in the
study, or patients with a contraindication to any of the study procedures;
- Patients with severe liver disease, renal insufficiency, congestive heart failure,
and/ or significant heart disease;
- Patients with a BMI over 42;
- Any patient that the investigators feel cannot comply with all study related
procedures.
- Patients who do not tolerate Percocet.
We found this trial at
1
site
550 1st Ave
New York, New York 10016
New York, New York 10016
(212) 263-7300
Principal Investigator: Prianka Desai, MD
Phone: 212-263-5072
New York University School of Medicine NYU School of Medicine has a proud history that...
Click here to add this to my saved trials
